PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 8, Pages e003093
Publisher
BMJ
Online
2021-08-10
DOI
10.1136/jitc-2021-003093
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells
- (2021) Yu-xiang Wang et al. Cell Death & Disease
- Integrating immunotherapy and targeted therapy in cancer treatment: Mechanistic insights and clinical implications
- (2020) Johann S. Bergholz et al. CLINICAL CANCER RESEARCH
- Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity
- (2020) Pu Sun et al. ACTA PHARMACOLOGICA SINICA
- Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors
- (2020) Hao-Yue Xiang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment
- (2020) Vitaliy Davidov et al. Frontiers in Immunology
- Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity
- (2020) Alison E. Ringel et al. CELL
- Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
- (2019) Ariella B. Hanker et al. Cancer Discovery
- The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
- (2019) Stalin Chellappa et al. JOURNAL OF IMMUNOLOGY
- PI 3K δ is a Treg target in cancer immunotherapy
- (2019) Ee Lyn Lim et al. IMMUNOLOGY
- Comprehensive Integration of Single-Cell Data
- (2019) Tim Stuart et al. CELL
- Alpelisib: First Global Approval
- (2019) Anthony Markham DRUGS
- Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer
- (2019) Nithya Sivaram et al. JOURNAL OF CLINICAL INVESTIGATION
- PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
- (2019) Ali S. Alzahrani SEMINARS IN CANCER BIOLOGY
- PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment
- (2019) Jia-jie Shi et al. CANCER LETTERS
- For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors
- (2019) Buchanan et al. Biomolecules
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer
- (2018) Xue-ling Liu et al. CANCER LETTERS
- The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
- (2018) Dearbhaile C. Collins et al. CURRENT CANCER DRUG TARGETS
- FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity
- (2018) Theresa L. Whiteside EXPERT OPINION ON THERAPEUTIC TARGETS
- Fatty acid synthase (FASN) as a therapeutic target in breast cancer
- (2017) Javier A. Menendez et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
- (2016) Jiqing Sai et al. CLINICAL CANCER RESEARCH
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences
- (2016) Kui Yang et al. TRENDS IN BIOCHEMICAL SCIENCES
- Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer
- (2016) Yujun Hao et al. Nature Communications
- Macrophage PI3K Drives Pancreatic Ductal Adenocarcinoma Progression
- (2016) M. M. Kaneda et al. Cancer Discovery
- Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
- (2015) Q. Yang et al. CLINICAL CANCER RESEARCH
- Short communication: Effect of inhibition of fatty acid synthase on triglyceride accumulation and effect on lipid metabolism genes in goat mammary epithelial cells
- (2015) J.J. Zhu et al. JOURNAL OF DAIRY SCIENCE
- What is synergy? The Saariselkä agreement revisited
- (2015) Jing Tang et al. Frontiers in Pharmacology
- Genetic Analysis of the Role of the PI3K-Akt Pathway in Lipopolysaccharide-Induced Cytokine and Tissue Factor Gene Expression in Monocytes/Macrophages
- (2014) J. P. Luyendyk et al. JOURNAL OF IMMUNOLOGY
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
- (2014) R. Abu-Eid et al. Cancer Immunology Research
- GSVA: gene set variation analysis for microarray and RNA-Seq data
- (2013) Sonja Hänzelmann et al. BMC BIOINFORMATICS
- Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer
- (2013) Xian Li et al. CANCER LETTERS
- Macrophage-Derived AIM Is Endocytosed into Adipocytes and Decreases Lipid Droplets via Inhibition of Fatty Acid Synthase Activity
- (2010) Jun Kurokawa et al. Cell Metabolism
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started